ReviewVaccines2020
Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 43 citations in OpenAlex.
- A colorimetric readout based on the PrestoBlue® dye as an objective method for measuring neutralizing antibodies against influenza virus in human serum samples.Biochemistry and biophysics reports · 2026Article
- Structural and immunological characterization of the H3 influenza hemagglutinin during antigenic drift.Nature communications · 2025Article
- Nanobodies: a new frontier in influenza virus neutralization.Folia microbiologica · 2025Review
- Passive Immunization in the Prevention and Treatment of Viral Infections.European journal of immunology · 2025Review
- Neuraminidase-specific antibodies drive differential cross-protection between contemporary FLUBV lineages.Science advances · 2025Article
- How Broadly Neutralising Antibodies Are Redefining Immunity to Influenza.Antibodies (Basel, Switzerland) · 2025Review
- Low-level human memory T and B cells recognising avian influenza hemagglutinins are poorly responsive to existing seasonal influenza vaccines.Clinical & translational immunology · 2025Article
- Article
- Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.Nature communications · 2024Article
- Article
- Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen.NPJ vaccines · 2023Article
- Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Influenza and Universal Vaccine Research in China.Viruses · 2022Review
- Inhibition of H1 and H5 Influenza A Virus Entry by Diverse Macrocyclic Peptides Targeting the Hemagglutinin Stem Region.ACS chemical biology · 2022Article
- Thermostable H1 hemagglutinin stem with M2e epitopes provides broad cross-protection against group1 and 2 influenza A viruses.Molecular therapy. Methods & clinical development · 2022Article
- Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and Heterosubtypic Protection by Influenza Virus Vaccination.Vaccines · 2022Article
- Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.Human vaccines & immunotherapeutics · 2022Review
- Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.Advanced nanobiomed research · 2022Article
- Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Influenza continues to be a public health threat despite the availability of annual vaccines. While vaccines are generally effective at inducing strain-specific immunity, they are sub-optimal or ineffective when drifted or novel pandemic strains arise due to sequence changes in the major surface glycoprotein hemagglutinin (HA). The discovery of a large number of antibodies targeting the highly conserved stem region of HAs that are capable of potently neutralizing a broad range of virus strains and subtypes suggests new ways to protect against influenza. The structural characterization of HA stem epitopes and broadly neutralizing antibody paratopes has enabled the design of novel proteins, mini-proteins, and peptides targeting the HA stem, thus providing a foundation for the design of new vaccines. In this narrative, we comprehensively review the current knowledge about stem-directed broadly neutralizing antibodies and the structural features contributing to virus neutralization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.